182 related articles for article (PubMed ID: 31422494)
21. Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression.
Lundstrom K; Abenavoli A; Malgaroli A; Ehrengruber MU
Mol Ther; 2003 Feb; 7(2):202-9. PubMed ID: 12597908
[TBL] [Abstract][Full Text] [Related]
22. Analysis of human immunodeficiency virus type 1 vector cis- and trans-acting elements production by means of Semliki Forest virus.
Del Vecchio C; Calistri A; Lombardi G; Celegato M; Biasolo MA; Palù G; Parolin C
Gene Ther; 2009 Feb; 16(2):279-90. PubMed ID: 19037240
[TBL] [Abstract][Full Text] [Related]
23. Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA.
Rolls MM; Webster P; Balba NH; Rose JK
Cell; 1994 Nov; 79(3):497-506. PubMed ID: 7954815
[TBL] [Abstract][Full Text] [Related]
24. Biogenesis of type I cytopathic vacuoles in Semliki Forest virus-infected BHK cells.
Peränen J; Kääriäinen L
J Virol; 1991 Mar; 65(3):1623-7. PubMed ID: 1825342
[TBL] [Abstract][Full Text] [Related]
25. Vesicular stomatitis virus glycoprotein: a transducing coat for SFV-based RNA vectors.
Dorange F; Piver E; Bru T; Collin C; Roingeard P; Pagès JC
J Gene Med; 2004 Sep; 6(9):1014-22. PubMed ID: 15352074
[TBL] [Abstract][Full Text] [Related]
26. Transient expression of rabies virus G-glycoprotein using BHK-21 cells cultured in suspension.
Fernández-Núñez EG; de Rezende AG; Puglia AL; Leme J; Boldorini VL; Caricati CP; Tonso A
Biotechnol Lett; 2015 Jun; 37(6):1153-63. PubMed ID: 25700821
[TBL] [Abstract][Full Text] [Related]
27. Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA.
Fournier P; Zeng J; Schirrmacher V
Int J Oncol; 2003 Sep; 23(3):673-80. PubMed ID: 12888903
[TBL] [Abstract][Full Text] [Related]
28. Expression of mammalian membrane proteins in mammalian cells using Semliki Forest virus vectors.
Lundstrom K
Methods Mol Biol; 2010; 601():149-63. PubMed ID: 20099145
[TBL] [Abstract][Full Text] [Related]
29. High cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules.
Zeng J; Fournier P; Schirrmacher V
Int J Oncol; 2004 Aug; 25(2):293-302. PubMed ID: 15254725
[TBL] [Abstract][Full Text] [Related]
30. Semliki Forest virus-derived virus-like particles: characterization of their production and transduction pathways.
Diatta A; Piver E; Collin C; Vaudin P; Pagès JC
J Gen Virol; 2005 Nov; 86(Pt 11):3129-3136. PubMed ID: 16227236
[TBL] [Abstract][Full Text] [Related]
31. Magnetic nanoparticles for efficient cell transduction with Semliki Forest virus.
Kurena B; Vežāne A; Skrastiņa D; Trofimova O; Zajakina A
J Virol Methods; 2017 Jul; 245():28-34. PubMed ID: 28315379
[TBL] [Abstract][Full Text] [Related]
32. Mobilization of full-length Semliki Forest virus replicon by retrovirus particles.
Piver E; Collin C; Renault N; Bru T; Pagès JC
J Virol; 2006 Oct; 80(19):9889-95. PubMed ID: 16973593
[TBL] [Abstract][Full Text] [Related]
33. Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector.
Murphy AM; Sheahan BJ; Atkins GJ
Int J Cancer; 2001 Nov; 94(4):572-8. PubMed ID: 11745446
[TBL] [Abstract][Full Text] [Related]
34. Improved Semliki Forest virus vectors for receptor research and gene therapy.
Lundstrom K; Ziltener P; Hermann D; Schweitzer C; Richards JG; Jenck F
J Recept Signal Transduct Res; 2001 Feb; 21(1):55-70. PubMed ID: 11693173
[TBL] [Abstract][Full Text] [Related]
35. Noncytopathic flavivirus replicon RNA-based system for expression and delivery of heterologous genes.
Varnavski AN; Khromykh AA
Virology; 1999 Mar; 255(2):366-75. PubMed ID: 10069962
[TBL] [Abstract][Full Text] [Related]
36. Differential Phosphatidylinositol-3-Kinase-Akt-mTOR Activation by Semliki Forest and Chikungunya Viruses Is Dependent on nsP3 and Connected to Replication Complex Internalization.
Thaa B; Biasiotto R; Eng K; Neuvonen M; Götte B; Rheinemann L; Mutso M; Utt A; Varghese F; Balistreri G; Merits A; Ahola T; McInerney GM
J Virol; 2015 Nov; 89(22):11420-37. PubMed ID: 26339054
[TBL] [Abstract][Full Text] [Related]
37. Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors.
Wang HC; An HJ; Yu YZ; Xu Q
Immunol Lett; 2015 Feb; 163(2):206-13. PubMed ID: 25102364
[TBL] [Abstract][Full Text] [Related]
38. RNA interference-mediated inhibition of Semliki Forest virus replication in mammalian cells.
Seyhan AA; Alizadeh BN; Lundstrom K; Johnston BH
Oligonucleotides; 2007; 17(4):473-84. PubMed ID: 18095875
[TBL] [Abstract][Full Text] [Related]
39. Development of a new noncytopathic Semliki Forest virus vector providing high expression levels and stability.
Casales E; Rodriguez-Madoz JR; Ruiz-Guillen M; Razquin N; Cuevas Y; Prieto J; Smerdou C
Virology; 2008 Jun; 376(1):242-51. PubMed ID: 18442838
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of various serum and animal protein free media for the production of a veterinary rabies vaccine in BHK-21 cells.
Kallel H; Jouini A; Majoul S; Rourou S
J Biotechnol; 2002 May; 95(3):195-204. PubMed ID: 12007860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
